Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Buy
71
MEHCQ Quote, Financials, Valuation and Earnings
Last price:
$3.10
Seasonality move
:
-18.12%
Day range:
$2.93 - $3.44
52-week range:
$0.47 - $12.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.40x
P/B ratio:
1.41x
Volume:
446.2K
Avg. volume:
388.5K
1-year change:
-67.62%
Market cap:
$88.5M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MEHCQ
23andMe Holding
|
-- | -- | -- | -- | -- |
|
CTSO
CytoSorbents
|
$9M | -$0.07 | 10.68% | -41.38% | $5.00 |
|
DCTH
Delcath Systems
|
$16.8M | $0.03 | 179.13% | -93.78% | $24.08 |
|
ISPC
iSpecimen
|
$2.9M | -- | 6.09% | -- | -- |
|
RDNT
RadNet
|
$443M | -$0.13 | 6.44% | -227.93% | $72.00 |
|
STRR
Star Equity Holdings
|
$16.4M | -$0.25 | 24.23% | -43.28% | $8.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MEHCQ
23andMe Holding
|
$3.30 | -- | $88.5M | -- | $0.00 | 0% | 0.40x |
|
CTSO
CytoSorbents
|
$0.85 | $5.00 | $52.9M | -- | $0.00 | 0% | 1.34x |
|
DCTH
Delcath Systems
|
$16.11 | $24.08 | $561.1M | -- | $0.00 | 0% | 9.89x |
|
ISPC
iSpecimen
|
$1.07 | -- | $2.7M | -- | $0.00 | 0% | 0.18x |
|
RDNT
RadNet
|
$56.61 | $72.00 | $4.2B | 1,513.25x | $0.00 | 0% | 2.30x |
|
STRR
Star Equity Holdings
|
$2.00 | $8.50 | $6.4M | 0.75x | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MEHCQ
23andMe Holding
|
-- | 2.368 | -- | -- |
|
CTSO
CytoSorbents
|
49.38% | 1.160 | 22.69% | 1.98x |
|
DCTH
Delcath Systems
|
-- | 2.997 | -- | 13.86x |
|
ISPC
iSpecimen
|
-- | 3.745 | -- | 0.28x |
|
RDNT
RadNet
|
52.93% | 3.132 | 25.47% | 1.88x |
|
STRR
Star Equity Holdings
|
18.39% | -0.314 | 40.47% | 0.69x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MEHCQ
23andMe Holding
|
-- | -- | -- | -- | -- | -- |
|
CTSO
CytoSorbents
|
$6.2M | -$3.9M | -58.93% | -106.57% | -10.01% | -$3.5M |
|
DCTH
Delcath Systems
|
$16.9M | $642K | -37.34% | -40.28% | 3.25% | $2.1M |
|
ISPC
iSpecimen
|
$400.2K | -$1.6M | -239.85% | -249.02% | -154.88% | -$1.1M |
|
RDNT
RadNet
|
$17.9M | -$17.6M | -1.55% | -2.91% | -3.37% | -$7.4M |
|
STRR
Star Equity Holdings
|
$3.1M | -$2.8M | -13.58% | -15.99% | -22.03% | $200K |
23andMe Holding vs. Competitors
-
Which has Higher Returns MEHCQ or CTSO?
CytoSorbents has a net margin of -- compared to 23andMe Holding's net margin of -16.94%. 23andMe Holding's return on equity of -- beat CytoSorbents's return on equity of -106.57%.
Company Gross Margin Earnings Per Share Invested Capital MEHCQ23andMe Holding-- -- -- CTSOCytoSorbents71.13% -$0.02 $28.7M -
What do Analysts Say About MEHCQ or CTSO?
23andMe Holding has a consensus price target of --, signalling downside risk potential of -36.97%. On the other hand CytoSorbents has an analysts' consensus of $5.00 which suggests that it could grow by 491.72%. Given that CytoSorbents has higher upside potential than 23andMe Holding, analysts believe CytoSorbents is more attractive than 23andMe Holding.
Company Buy Ratings Hold Ratings Sell Ratings MEHCQ23andMe Holding0 0 0 CTSOCytoSorbents1 1 0 -
Is MEHCQ or CTSO More Risky?
23andMe Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CytoSorbents has a beta of 1.171, suggesting its more volatile than the S&P 500 by 17.12%.
-
Which is a Better Dividend Stock MEHCQ or CTSO?
23andMe Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 23andMe Holding pays -- of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEHCQ or CTSO?
23andMe Holding quarterly revenues are --, which are smaller than CytoSorbents quarterly revenues of $8.7M. 23andMe Holding's net income of -- is lower than CytoSorbents's net income of -$1.5M. Notably, 23andMe Holding's price-to-earnings ratio is -- while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 23andMe Holding is 0.40x versus 1.34x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEHCQ23andMe Holding0.40x -- -- -- CTSOCytoSorbents1.34x -- $8.7M -$1.5M
-
Which has Higher Returns MEHCQ or DCTH?
Delcath Systems has a net margin of -- compared to 23andMe Holding's net margin of 5.4%. 23andMe Holding's return on equity of -- beat Delcath Systems's return on equity of -40.28%.
Company Gross Margin Earnings Per Share Invested Capital MEHCQ23andMe Holding-- -- -- DCTHDelcath Systems85.62% $0.03 $80.2M -
What do Analysts Say About MEHCQ or DCTH?
23andMe Holding has a consensus price target of --, signalling downside risk potential of -36.97%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 49.46%. Given that Delcath Systems has higher upside potential than 23andMe Holding, analysts believe Delcath Systems is more attractive than 23andMe Holding.
Company Buy Ratings Hold Ratings Sell Ratings MEHCQ23andMe Holding0 0 0 DCTHDelcath Systems4 0 0 -
Is MEHCQ or DCTH More Risky?
23andMe Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.805%.
-
Which is a Better Dividend Stock MEHCQ or DCTH?
23andMe Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 23andMe Holding pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEHCQ or DCTH?
23andMe Holding quarterly revenues are --, which are smaller than Delcath Systems quarterly revenues of $19.8M. 23andMe Holding's net income of -- is lower than Delcath Systems's net income of $1.1M. Notably, 23andMe Holding's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 23andMe Holding is 0.40x versus 9.89x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEHCQ23andMe Holding0.40x -- -- -- DCTHDelcath Systems9.89x -- $19.8M $1.1M
-
Which has Higher Returns MEHCQ or ISPC?
iSpecimen has a net margin of -- compared to 23andMe Holding's net margin of -156.82%. 23andMe Holding's return on equity of -- beat iSpecimen's return on equity of -249.02%.
Company Gross Margin Earnings Per Share Invested Capital MEHCQ23andMe Holding-- -- -- ISPCiSpecimen37.85% -$0.71 $1.7M -
What do Analysts Say About MEHCQ or ISPC?
23andMe Holding has a consensus price target of --, signalling downside risk potential of -36.97%. On the other hand iSpecimen has an analysts' consensus of -- which suggests that it could grow by 5507.48%. Given that iSpecimen has higher upside potential than 23andMe Holding, analysts believe iSpecimen is more attractive than 23andMe Holding.
Company Buy Ratings Hold Ratings Sell Ratings MEHCQ23andMe Holding0 0 0 ISPCiSpecimen0 0 0 -
Is MEHCQ or ISPC More Risky?
23andMe Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iSpecimen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MEHCQ or ISPC?
23andMe Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iSpecimen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 23andMe Holding pays -- of its earnings as a dividend. iSpecimen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEHCQ or ISPC?
23andMe Holding quarterly revenues are --, which are smaller than iSpecimen quarterly revenues of $1.1M. 23andMe Holding's net income of -- is lower than iSpecimen's net income of -$1.7M. Notably, 23andMe Holding's price-to-earnings ratio is -- while iSpecimen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 23andMe Holding is 0.40x versus 0.18x for iSpecimen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEHCQ23andMe Holding0.40x -- -- -- ISPCiSpecimen0.18x -- $1.1M -$1.7M
-
Which has Higher Returns MEHCQ or RDNT?
RadNet has a net margin of -- compared to 23andMe Holding's net margin of -8.05%. 23andMe Holding's return on equity of -- beat RadNet's return on equity of -2.91%.
Company Gross Margin Earnings Per Share Invested Capital MEHCQ23andMe Holding-- -- -- RDNTRadNet3.8% -$0.51 $2.1B -
What do Analysts Say About MEHCQ or RDNT?
23andMe Holding has a consensus price target of --, signalling downside risk potential of -36.97%. On the other hand RadNet has an analysts' consensus of $72.00 which suggests that it could grow by 27.19%. Given that RadNet has higher upside potential than 23andMe Holding, analysts believe RadNet is more attractive than 23andMe Holding.
Company Buy Ratings Hold Ratings Sell Ratings MEHCQ23andMe Holding0 0 0 RDNTRadNet4 0 0 -
Is MEHCQ or RDNT More Risky?
23andMe Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RadNet has a beta of 1.465, suggesting its more volatile than the S&P 500 by 46.472%.
-
Which is a Better Dividend Stock MEHCQ or RDNT?
23andMe Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RadNet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 23andMe Holding pays -- of its earnings as a dividend. RadNet pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEHCQ or RDNT?
23andMe Holding quarterly revenues are --, which are smaller than RadNet quarterly revenues of $471.4M. 23andMe Holding's net income of -- is lower than RadNet's net income of -$37.9M. Notably, 23andMe Holding's price-to-earnings ratio is -- while RadNet's PE ratio is 1,513.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 23andMe Holding is 0.40x versus 2.30x for RadNet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEHCQ23andMe Holding0.40x -- -- -- RDNTRadNet2.30x 1,513.25x $471.4M -$37.9M
-
Which has Higher Returns MEHCQ or STRR?
Star Equity Holdings has a net margin of -- compared to 23andMe Holding's net margin of -9.1%. 23andMe Holding's return on equity of -- beat Star Equity Holdings's return on equity of -15.99%.
Company Gross Margin Earnings Per Share Invested Capital MEHCQ23andMe Holding-- -- -- STRRStar Equity Holdings24.27% -$0.52 $73.2M -
What do Analysts Say About MEHCQ or STRR?
23andMe Holding has a consensus price target of --, signalling downside risk potential of -36.97%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 324.92%. Given that Star Equity Holdings has higher upside potential than 23andMe Holding, analysts believe Star Equity Holdings is more attractive than 23andMe Holding.
Company Buy Ratings Hold Ratings Sell Ratings MEHCQ23andMe Holding0 0 0 STRRStar Equity Holdings1 0 0 -
Is MEHCQ or STRR More Risky?
23andMe Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.92%.
-
Which is a Better Dividend Stock MEHCQ or STRR?
23andMe Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 23andMe Holding pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.
-
Which has Better Financial Ratios MEHCQ or STRR?
23andMe Holding quarterly revenues are --, which are smaller than Star Equity Holdings quarterly revenues of $12.9M. 23andMe Holding's net income of -- is lower than Star Equity Holdings's net income of -$1.2M. Notably, 23andMe Holding's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 23andMe Holding is 0.40x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEHCQ23andMe Holding0.40x -- -- -- STRRStar Equity Holdings0.11x 0.75x $12.9M -$1.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…
Where Will Coinbase Stock Be in 5 Years?
If you’ve been anywhere near the crypto world over the…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
55
SBET alert for May 27
SharpLink Gaming [SBET] is up 454.46% over the past day.
Buy
57
RGC alert for May 27
Regencell Bioscience Holdings [RGC] is down 9.77% over the past day.
Buy
90
OKLO alert for May 27
Oklo [OKLO] is up 10.05% over the past day.
